Suresh Pattathil succeeds S Sridhar who has been the President of OPPI since February 2021

The Organisation of Pharmaceutical Producers of India (OPPI), which represents the research-based pharmaceutical companies, has elected Suresh Pattathil as its next President today. The term is for a period of two years and is effective from September 26, 2022. Suresh takes over from S Sridhar, MD Pfizer India Limited, who has been with the association since 2021.

Suresh Pattathil is the Managing Director and General Manager, Allergan, an AbbVie Company*, a dynamic biopharmaceutical company, which discovers and delivers innovative medicines and solutions that address complex health issues and enhances people’s lives. He is responsible for commercial operations in India & South Asia markets. With more than 30 years of experience in the pharmaceutical industry, Suresh has held several senior management positions in companies such as Pfizer, Schering Plough, MSD and Ferring.

Speaking on his appointment, Mr. Suresh Pattathil shared, “I am honored to take this responsibility at this critical juncture for healthcare in the country. Health today, has become a priority for the government, and OPPI, as an association, focused on research and innovation, is working towards solving some of the most pressing healthcare needs. I look forward to making a difference to patients and the industry as OPPI works with the government to enable healthcare access. I thank the members of OPPI’s Executive Committee who selected me for this role.”

Welcoming Suresh as President, Mr. S Sridhar, said, “It has been my honour to serve as the President at OPPI for the past year and a half driving forth its vision and mission of bolstering innovation and R&D in India’s emerging healthcare sector. As I move on, I pass on the baton to my colleague Mr Suresh Pattathil, who I am sure would steer OPPI in the right direction of enabling research and collaborations, thus build the pharmaceutical sector with his insights and great contributions. I wish him all the best and sincerely hope to see OPPI soar to great heights of success under his able guidance.”

Commenting on the development, Mr. Vivek Sehgal, Director General, OPPI, said, “I would like to express my deepest gratitude to Sridhar for his unwavering commitment towards achieving OPPI’s vision of expanding healthcare in India. The OPPI family wishes him all the luck in his future endeavors.

I welcome Suresh on-board and am confident that with his expertise, we will be able to achieve many more milestones and remain committed to enhancing OPPI’s leadership in bringing innovative drugs and new therapies for unmet medical needs. He has always been a strong voice for healthcare transformation in the country and under his able leadership we will continue to put in efforts to optimize patient outcomes by creating an environment conducive to innovation and growth as well as continue to engage deeply with the government stakeholders.”

Most recently Suresh was the Chief Executive Officer for Ferring Pharmaceuticals India with responsibility for Commercial operations, Research & Development center and setting up a pilot plant and manufacturing facility in Hyderabad. He has a broad experience in both specialty as well as mass therapeutic areas and in launching global products successfully in India.